FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594244082> ?p ?o ?g. }

• W2594244082 abstract "Patients with metastatic prostate cancer (PCa) have effective therapy options, but none of them are curative. Thus, their mortality rates are persistently high. Essential to furthering our progress in PCa research and therapy development is a spectrum of models that reflect the heterogeneity of the disease at each tumor site as well as the different histological variants of PCa (e.g., adenocarcinoma, small cell carcinoma). To address this challenge, we developed a strategy to establish PCa patient-derived xenografts (PDXs), using PCa tissue specimens taken from PCa sites demonstrating clinical progression. This approach provided a diverse repository of PDXs that can be linked prospectively with clinical progression and led to the identification of clinically relevant therapy targets and have proven valuable for testing drugs. We studied the first 50 PDXs developed under our program to a) define the histopathological features of paired human PCa and corresponding PDXs applying the clinically defined morphological characterization groupings of human cancer to the PDX tumors; b) assess the expression of genes known to play roles in PCa pathogenesis (e.g., androgen receptor, PTEN, ETS gene fusions) in PDXs and the human tumors of origin using immunohistochemistry and fluorescence in situ hybridization and c) perform array comparative genomic hybridization to 42 PDXs. We found that the histopathological and molecular pattern of these PDXs maintain the fidelity with the human tumor of origin. Furthermore, of the 50 cases studied, 32 (64%) were adenocarcinomas, and 16 (32%) were small cell carcinomas, poorly differentiated neuroendocrine carcinomas or mixed adenocarcinoma/ small cell carcinomas. In our cohort, we also have one sarcomatoid tumor and one ductal adenocarcinoma. Of the 32 adenocarcinomas in this cohort, 26 were AR-positive (81%), and 11 of the 27 AR-positive adenocarcinomas (41%) had aberrant expression of genes frequently involved in recurrent rearrangement (e.g., ERG, ETV1, ETV5). Also, SCCs and poorly differentiated neuroendocrine carcinomas did not express AR and were negative for ERG. This distribution recapitulates that of human PCa in the general population. Comparative genomic hybridization demonstrated gains and losses previously reported in PCa with a defined cluster of genomic aberrations. Significant differences in oncogenic pathways activation in pairs of PDXs derived from different areas of the same tumor suggesting divergent cellular progression. Finally, using this platform, we identified a focal deletion of speckle-type POZ protein-like (SPOPL) gene in 7/28 PDX. SPOPL is a MATH-BTB protein that shares an overall 85% sequence identity with SPOP (a SPOPL paralog). SPOP was recently reported to be mutated in about 8% of PCa and to define a molecular subclass of PCa. No mutations were found in SPOP in our cohort. In support of our findings, deletions on SPOPL were also found in about 7% of the PCa in TCGA data suggesting that our cohort is a reliable platform for discovery. In conclusion, we have developed a dynamic repository of clinically annotated samples that can be used as a discovery platform. Furthermore, these clinically annotated samples can be linked prospectively to clinical progression/response to therapy and thus will help define therapeutic targets for subpopulations of men and to identify likely responders to previous and upcoming therapies. Citation Format: Nallasivam Palanisamy, Jun Yang, Xinhai Wan, Elsa M. li Ning Tapia, John C. Araujo, Eleni Efstathiou, Estefania Labanca, Louis Pisters, Ana Aparicio, Ritu Bhalla, Scott Tomlins, Lakshmi P. Kunju, Arul Chinnaiyan, Christopher J. Logothetis, Patricia Troncoso, Nora M. Navone. Analyses of a prostate cancer patient-derived xenografts series, a resource for translational research. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr A03." @default.
• W2594244082 created "2017-03-16" @default.
• W2594244082 creator A5008820123 @default.
• W2594244082 creator A5021183845 @default.
• W2594244082 creator A5033409732 @default.
• W2594244082 creator A5033415518 @default.
• W2594244082 creator A5036272242 @default.
• W2594244082 creator A5037041732 @default.
• W2594244082 creator A5042167871 @default.
• W2594244082 creator A5045545790 @default.
• W2594244082 creator A5046472038 @default.
• W2594244082 creator A5048915309 @default.
• W2594244082 creator A5049047012 @default.
• W2594244082 creator A5059895645 @default.
• W2594244082 creator A5065564993 @default.
• W2594244082 creator A5068238406 @default.
• W2594244082 creator A5078910130 @default.
• W2594244082 creator A5087963478 @default.
• W2594244082 date "2016-08-14" @default.
• W2594244082 modified "2023-09-24" @default.
• W2594244082 title "Abstract A03: Analyses of a prostate cancer patient-derived xenografts series, a resource for translational research" @default.
• W2594244082 doi "https://doi.org/10.1158/1557-3265.pdx16-a03" @default.
• W2594244082 hasPublicationYear "2016" @default.
• W2594244082 type Work @default.
• W2594244082 sameAs 2594244082 @default.
• W2594244082 citedByCount "0" @default.
• W2594244082 crossrefType "proceedings-article" @default.
• W2594244082 hasAuthorship W2594244082A5008820123 @default.
• W2594244082 hasAuthorship W2594244082A5021183845 @default.
• W2594244082 hasAuthorship W2594244082A5033409732 @default.
• W2594244082 hasAuthorship W2594244082A5033415518 @default.
• W2594244082 hasAuthorship W2594244082A5036272242 @default.
• W2594244082 hasAuthorship W2594244082A5037041732 @default.
• W2594244082 hasAuthorship W2594244082A5042167871 @default.
• W2594244082 hasAuthorship W2594244082A5045545790 @default.
• W2594244082 hasAuthorship W2594244082A5046472038 @default.
• W2594244082 hasAuthorship W2594244082A5048915309 @default.
• W2594244082 hasAuthorship W2594244082A5049047012 @default.
• W2594244082 hasAuthorship W2594244082A5059895645 @default.
• W2594244082 hasAuthorship W2594244082A5065564993 @default.
• W2594244082 hasAuthorship W2594244082A5068238406 @default.
• W2594244082 hasAuthorship W2594244082A5078910130 @default.
• W2594244082 hasAuthorship W2594244082A5087963478 @default.
• W2594244082 hasConcept C104317684 @default.
• W2594244082 hasConcept C121608353 @default.
• W2594244082 hasConcept C126322002 @default.
• W2594244082 hasConcept C142724271 @default.
• W2594244082 hasConcept C143998085 @default.
• W2594244082 hasConcept C190283241 @default.
• W2594244082 hasConcept C2776235491 @default.
• W2594244082 hasConcept C2777542201 @default.
• W2594244082 hasConcept C2777609662 @default.
• W2594244082 hasConcept C2780192828 @default.
• W2594244082 hasConcept C2781182431 @default.
• W2594244082 hasConcept C30481170 @default.
• W2594244082 hasConcept C502942594 @default.
• W2594244082 hasConcept C55493867 @default.
• W2594244082 hasConcept C71924100 @default.
• W2594244082 hasConcept C86554907 @default.
• W2594244082 hasConcept C86803240 @default.
• W2594244082 hasConceptScore W2594244082C104317684 @default.
• W2594244082 hasConceptScore W2594244082C121608353 @default.
• W2594244082 hasConceptScore W2594244082C126322002 @default.
• W2594244082 hasConceptScore W2594244082C142724271 @default.
• W2594244082 hasConceptScore W2594244082C143998085 @default.
• W2594244082 hasConceptScore W2594244082C190283241 @default.
• W2594244082 hasConceptScore W2594244082C2776235491 @default.
• W2594244082 hasConceptScore W2594244082C2777542201 @default.
• W2594244082 hasConceptScore W2594244082C2777609662 @default.
• W2594244082 hasConceptScore W2594244082C2780192828 @default.
• W2594244082 hasConceptScore W2594244082C2781182431 @default.
• W2594244082 hasConceptScore W2594244082C30481170 @default.
• W2594244082 hasConceptScore W2594244082C502942594 @default.
• W2594244082 hasConceptScore W2594244082C55493867 @default.
• W2594244082 hasConceptScore W2594244082C71924100 @default.
• W2594244082 hasConceptScore W2594244082C86554907 @default.
• W2594244082 hasConceptScore W2594244082C86803240 @default.
• W2594244082 hasLocation W25942440821 @default.
• W2594244082 hasOpenAccess W2594244082 @default.
• W2594244082 hasPrimaryLocation W25942440821 @default.
• W2594244082 hasRelatedWork W1788100462 @default.
• W2594244082 hasRelatedWork W1972990461 @default.
• W2594244082 hasRelatedWork W2020360679 @default.
• W2594244082 hasRelatedWork W2094822790 @default.
• W2594244082 hasRelatedWork W2318906201 @default.
• W2594244082 hasRelatedWork W2501425795 @default.
• W2594244082 hasRelatedWork W2591639835 @default.
• W2594244082 hasRelatedWork W2592672980 @default.
• W2594244082 hasRelatedWork W2741745095 @default.
• W2594244082 hasRelatedWork W2885532732 @default.
• W2594244082 hasRelatedWork W2886353424 @default.
• W2594244082 hasRelatedWork W2886614406 @default.
• W2594244082 hasRelatedWork W2953615706 @default.
• W2594244082 hasRelatedWork W2954627849 @default.
• W2594244082 hasRelatedWork W2968252749 @default.
• W2594244082 hasRelatedWork W3080128047 @default.
• W2594244082 hasRelatedWork W3082763273 @default.
• W2594244082 hasRelatedWork W3158020757 @default.
• W2594244082 hasRelatedWork W3160112606 @default.
• W2594244082 hasRelatedWork W3181915522 @default.

• next